Cargando…
Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial
BACKGROUND: Paracetamol’s solubility is achieved by adding to the excipient sodium salts, either as bicarbonate, carbonate or citrate. As the relationship between salt and hypertension is well known, due to the sodium content it has raised a hypothesis that may interfere with the control of that ris...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676099/ https://www.ncbi.nlm.nih.gov/pubmed/26654907 http://dx.doi.org/10.1186/s12872-015-0161-7 |
_version_ | 1782405110532407296 |
---|---|
author | Benitez-Camps, Mencia Vinyoles-Bargalló, Ernest Rebagliato-Nadal, Oriol Morros-Pedrós, Rosa Pera-Pujadas, Helena Dalfó-Baqué, Antoni López-Pavón, Ignacio Roca-Sánchez, Carlos Coma-Carbó, Rosa Maria De La Figuera Von Wichmann, Mariano Mengual-Martínez, Lucas Yuste-Marco, Carmen Teixidó-Colet, Montserrat Pepió i Vilaubí, Josep M. Ciurana-Tost, Riera Pou-Vila, Rosa Vila-Coll, Ma Antònia Bordas-Julve, Josep Maria Aragonès-Forès, Rosa Pelegrina-Rodríguez, Francisco Javier Agudo-Ugena, Josep Blanco-Mata, Carlos de la Iglesia Berrojalbiz, Jon Burgos-Alonso, Natalia Gómez-Fernández, Maria Cruz |
author_facet | Benitez-Camps, Mencia Vinyoles-Bargalló, Ernest Rebagliato-Nadal, Oriol Morros-Pedrós, Rosa Pera-Pujadas, Helena Dalfó-Baqué, Antoni López-Pavón, Ignacio Roca-Sánchez, Carlos Coma-Carbó, Rosa Maria De La Figuera Von Wichmann, Mariano Mengual-Martínez, Lucas Yuste-Marco, Carmen Teixidó-Colet, Montserrat Pepió i Vilaubí, Josep M. Ciurana-Tost, Riera Pou-Vila, Rosa Vila-Coll, Ma Antònia Bordas-Julve, Josep Maria Aragonès-Forès, Rosa Pelegrina-Rodríguez, Francisco Javier Agudo-Ugena, Josep Blanco-Mata, Carlos de la Iglesia Berrojalbiz, Jon Burgos-Alonso, Natalia Gómez-Fernández, Maria Cruz |
author_sort | Benitez-Camps, Mencia |
collection | PubMed |
description | BACKGROUND: Paracetamol’s solubility is achieved by adding to the excipient sodium salts, either as bicarbonate, carbonate or citrate. As the relationship between salt and hypertension is well known, due to the sodium content it has raised a hypothesis that may interfere with the control of that risk factor. Therefore, the objective of this study is to evaluate the effect on blood pressure of effervescent paracetamol compared to non-effervescent, in hypertensive patients. METHODS/DESIGN: This is the protocol of a phase IV multicenter clinical trial, randomized, controlled, crossover, open, which will compare the effect of two different formulations of paracetamol (effervescent or non-effervescent) in the blood pressure of hypertensive patients, with a seven weeks follow up. 49 controlled hypertensive patients will be included (clinical BP lower than 150 and 95 mmHg, and lower than 135 mmHg and 85 mmHg in patients with diabetes or a history of cardiovascular event, and daytime ambulatory measurements lower than 140 and 90 mmHg) and mild to moderate pain (Visual Analog Scale between 1 and 4). The study was approved by the ethics committee of the Fundació Jordi Gol i Gurina and following standards of good clinical practice. The primary endpoint will be the variations in systolic BP in 24 h Ambulatory Blood Pressure Monitoring, considering significant differences 2 or more mmHg among those treated with non-effervescent and effervescent formulations. Intention-to-treat and per-protocol analysis will be held. DISCUSSION: Despite the broad recommendation not to use effervescent drugs in patients with hypertension, there are relatively little studies that show exactly this pressor effect due to sodium in salt that gives the effervescence of the product. This is the first clinical trial designed to study the effect of effervescence compared to the non-effervescent, in well-controlled hypertensive patients with mild to moderate pain, performed in routine clinical practice TRIAL REGISTRATION: NCT 02514538 |
format | Online Article Text |
id | pubmed-4676099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46760992015-12-12 Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial Benitez-Camps, Mencia Vinyoles-Bargalló, Ernest Rebagliato-Nadal, Oriol Morros-Pedrós, Rosa Pera-Pujadas, Helena Dalfó-Baqué, Antoni López-Pavón, Ignacio Roca-Sánchez, Carlos Coma-Carbó, Rosa Maria De La Figuera Von Wichmann, Mariano Mengual-Martínez, Lucas Yuste-Marco, Carmen Teixidó-Colet, Montserrat Pepió i Vilaubí, Josep M. Ciurana-Tost, Riera Pou-Vila, Rosa Vila-Coll, Ma Antònia Bordas-Julve, Josep Maria Aragonès-Forès, Rosa Pelegrina-Rodríguez, Francisco Javier Agudo-Ugena, Josep Blanco-Mata, Carlos de la Iglesia Berrojalbiz, Jon Burgos-Alonso, Natalia Gómez-Fernández, Maria Cruz BMC Cardiovasc Disord Study Protocol BACKGROUND: Paracetamol’s solubility is achieved by adding to the excipient sodium salts, either as bicarbonate, carbonate or citrate. As the relationship between salt and hypertension is well known, due to the sodium content it has raised a hypothesis that may interfere with the control of that risk factor. Therefore, the objective of this study is to evaluate the effect on blood pressure of effervescent paracetamol compared to non-effervescent, in hypertensive patients. METHODS/DESIGN: This is the protocol of a phase IV multicenter clinical trial, randomized, controlled, crossover, open, which will compare the effect of two different formulations of paracetamol (effervescent or non-effervescent) in the blood pressure of hypertensive patients, with a seven weeks follow up. 49 controlled hypertensive patients will be included (clinical BP lower than 150 and 95 mmHg, and lower than 135 mmHg and 85 mmHg in patients with diabetes or a history of cardiovascular event, and daytime ambulatory measurements lower than 140 and 90 mmHg) and mild to moderate pain (Visual Analog Scale between 1 and 4). The study was approved by the ethics committee of the Fundació Jordi Gol i Gurina and following standards of good clinical practice. The primary endpoint will be the variations in systolic BP in 24 h Ambulatory Blood Pressure Monitoring, considering significant differences 2 or more mmHg among those treated with non-effervescent and effervescent formulations. Intention-to-treat and per-protocol analysis will be held. DISCUSSION: Despite the broad recommendation not to use effervescent drugs in patients with hypertension, there are relatively little studies that show exactly this pressor effect due to sodium in salt that gives the effervescence of the product. This is the first clinical trial designed to study the effect of effervescence compared to the non-effervescent, in well-controlled hypertensive patients with mild to moderate pain, performed in routine clinical practice TRIAL REGISTRATION: NCT 02514538 BioMed Central 2015-12-10 /pmc/articles/PMC4676099/ /pubmed/26654907 http://dx.doi.org/10.1186/s12872-015-0161-7 Text en © Benitez-Camps et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Benitez-Camps, Mencia Vinyoles-Bargalló, Ernest Rebagliato-Nadal, Oriol Morros-Pedrós, Rosa Pera-Pujadas, Helena Dalfó-Baqué, Antoni López-Pavón, Ignacio Roca-Sánchez, Carlos Coma-Carbó, Rosa Maria De La Figuera Von Wichmann, Mariano Mengual-Martínez, Lucas Yuste-Marco, Carmen Teixidó-Colet, Montserrat Pepió i Vilaubí, Josep M. Ciurana-Tost, Riera Pou-Vila, Rosa Vila-Coll, Ma Antònia Bordas-Julve, Josep Maria Aragonès-Forès, Rosa Pelegrina-Rodríguez, Francisco Javier Agudo-Ugena, Josep Blanco-Mata, Carlos de la Iglesia Berrojalbiz, Jon Burgos-Alonso, Natalia Gómez-Fernández, Maria Cruz Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial |
title | Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial |
title_full | Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial |
title_fullStr | Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial |
title_full_unstemmed | Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial |
title_short | Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial |
title_sort | evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676099/ https://www.ncbi.nlm.nih.gov/pubmed/26654907 http://dx.doi.org/10.1186/s12872-015-0161-7 |
work_keys_str_mv | AT benitezcampsmencia evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT vinyolesbargalloernest evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT rebagliatonadaloriol evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT morrospedrosrosa evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT perapujadashelena evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT dalfobaqueantoni evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT lopezpavonignacio evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT rocasanchezcarlos evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT comacarborosamaria evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT delafigueravonwichmannmariano evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT mengualmartinezlucas evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT yustemarcocarmen evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT teixidocoletmontserrat evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT pepioivilaubijosepm evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT ciuranatostriera evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT pouvilarosa evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT vilacollmaantonia evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT bordasjulvejosepmaria evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT aragonesforesrosa evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT pelegrinarodriguezfranciscojavier evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT agudougenajosep evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT blancomatacarlos evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT delaiglesiaberrojalbizjon evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT burgosalonsonatalia evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial AT gomezfernandezmariacruz evaluationoftherelationshipbetweeneffervescentparacetamolandbloodpressureclinicaltrial |